Cargando…

Effect of the addition of a mental health specialist for evaluation of undiagnosed patients in centres for rare diseases (ZSE-DUO): a prospective, controlled trial with a two-phase cohort design

BACKGROUND: People with complex symptomatology but unclear diagnosis presenting to a centre for rare diseases (CRD) may present with mental (co-)morbidity. We hypothesised that combining an expert in somatic medicine with a mental health specialist working in tandem will improve the diagnostic outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Hebestreit, Helge, Lapstich, Anne-Marie, Brandstetter, Lilly, Krauth, Christian, Deckert, Jürgen, Haas, Kirsten, Pfister, Lisa, Witt, Stefanie, Schippers, Christopher, Dieris-Hirche, Jan, Maisch, Tim, Tüscher, Oliver, Bârlescu, Lavinia, Berger, Alexandra, Berneburg, Mark, Britz, Vanessa, Deibele, Anna, Graeßner, Holm, Gündel, Harald, Heuft, Gereon, Lücke, Thomas, Mundlos, Christine, Quitmann, Julia, Rutsch, Frank, Schubert, Katharina, Schulz, Jörg Bernhard, Schweiger, Susann, Zeidler, Cornelia, Zeltner, Lena, de Zwaan, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579280/
https://www.ncbi.nlm.nih.gov/pubmed/37855024
http://dx.doi.org/10.1016/j.eclinm.2023.102260
_version_ 1785121691178893312
author Hebestreit, Helge
Lapstich, Anne-Marie
Brandstetter, Lilly
Krauth, Christian
Deckert, Jürgen
Haas, Kirsten
Pfister, Lisa
Witt, Stefanie
Schippers, Christopher
Dieris-Hirche, Jan
Maisch, Tim
Tüscher, Oliver
Bârlescu, Lavinia
Berger, Alexandra
Berneburg, Mark
Britz, Vanessa
Deibele, Anna
Graeßner, Holm
Gündel, Harald
Heuft, Gereon
Lücke, Thomas
Mundlos, Christine
Quitmann, Julia
Rutsch, Frank
Schubert, Katharina
Schulz, Jörg Bernhard
Schweiger, Susann
Zeidler, Cornelia
Zeltner, Lena
de Zwaan, Martina
author_facet Hebestreit, Helge
Lapstich, Anne-Marie
Brandstetter, Lilly
Krauth, Christian
Deckert, Jürgen
Haas, Kirsten
Pfister, Lisa
Witt, Stefanie
Schippers, Christopher
Dieris-Hirche, Jan
Maisch, Tim
Tüscher, Oliver
Bârlescu, Lavinia
Berger, Alexandra
Berneburg, Mark
Britz, Vanessa
Deibele, Anna
Graeßner, Holm
Gündel, Harald
Heuft, Gereon
Lücke, Thomas
Mundlos, Christine
Quitmann, Julia
Rutsch, Frank
Schubert, Katharina
Schulz, Jörg Bernhard
Schweiger, Susann
Zeidler, Cornelia
Zeltner, Lena
de Zwaan, Martina
author_sort Hebestreit, Helge
collection PubMed
description BACKGROUND: People with complex symptomatology but unclear diagnosis presenting to a centre for rare diseases (CRD) may present with mental (co-)morbidity. We hypothesised that combining an expert in somatic medicine with a mental health specialist working in tandem will improve the diagnostic outcome. METHODS: Patients aged 12 years and older who presented to one of the 11 participating German CRDs with an unknown diagnosis were recruited into this prospective cohort trial with a two-phase cohort design. From October 1, 2018 to September 30, 2019, participants were allocated to standard care (SC, N = 684), and from October 1, 2019 to January 31, 2021 to innovative care (IC, N = 695). The cohorts consisted mainly of adult participants with only a minority of children included (N = 67). IC included the involvement of a mental health specialist in all aspects of care (e.g., assessing medical records, clinic visits, telehealth care, and case conferences). Clinicaltrials.gov identifier: NCT03563677. FINDINGS: The proportion of patients with diagnoses established within 12 months after the first visit to the CRD explaining the entire symptomatology (primary outcome) was 19% (N = 131 of 672) in the SC and 42% (N = 286 of 686) in the IC cohort (OR adjusted for centre effects 3.45 [95% CrI: 1.99–5.65]). The difference was mainly due to a higher prevalence of mental disorders and non-rare somatic diseases in the IC cohort. The median time to explaining diagnoses was one month shorter with IC (95% CrI: 1–2), and significantly more patients could be referred to local regular care in the IC (27.5%; N = 181 of 659) compared to the SC (12.3%; N = 81 of 658) cohort (OR adjusted for centre effects 2.70 [95% CrI: 2.02–3.60]). At 12-month follow-up, patient satisfaction with care was significantly higher in the IC compared to the SC cohort, while quality of life was not different between cohorts. INTERPRETATION: Our findings suggested that including a mental health specialist in the entire evaluation process of CRDs for undiagnosed adolescents and adults should become an integral part of the assessment of individuals with a suspected rare disease. FUNDING: The study was funded by the 10.13039/501100024399Global Innovation Fund from the Joint Federal Committee in Germany (Innovationsfonds des Gemeinsamen Bundesausschusses), grant number 01NVF17031.
format Online
Article
Text
id pubmed-10579280
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105792802023-10-18 Effect of the addition of a mental health specialist for evaluation of undiagnosed patients in centres for rare diseases (ZSE-DUO): a prospective, controlled trial with a two-phase cohort design Hebestreit, Helge Lapstich, Anne-Marie Brandstetter, Lilly Krauth, Christian Deckert, Jürgen Haas, Kirsten Pfister, Lisa Witt, Stefanie Schippers, Christopher Dieris-Hirche, Jan Maisch, Tim Tüscher, Oliver Bârlescu, Lavinia Berger, Alexandra Berneburg, Mark Britz, Vanessa Deibele, Anna Graeßner, Holm Gündel, Harald Heuft, Gereon Lücke, Thomas Mundlos, Christine Quitmann, Julia Rutsch, Frank Schubert, Katharina Schulz, Jörg Bernhard Schweiger, Susann Zeidler, Cornelia Zeltner, Lena de Zwaan, Martina eClinicalMedicine Articles BACKGROUND: People with complex symptomatology but unclear diagnosis presenting to a centre for rare diseases (CRD) may present with mental (co-)morbidity. We hypothesised that combining an expert in somatic medicine with a mental health specialist working in tandem will improve the diagnostic outcome. METHODS: Patients aged 12 years and older who presented to one of the 11 participating German CRDs with an unknown diagnosis were recruited into this prospective cohort trial with a two-phase cohort design. From October 1, 2018 to September 30, 2019, participants were allocated to standard care (SC, N = 684), and from October 1, 2019 to January 31, 2021 to innovative care (IC, N = 695). The cohorts consisted mainly of adult participants with only a minority of children included (N = 67). IC included the involvement of a mental health specialist in all aspects of care (e.g., assessing medical records, clinic visits, telehealth care, and case conferences). Clinicaltrials.gov identifier: NCT03563677. FINDINGS: The proportion of patients with diagnoses established within 12 months after the first visit to the CRD explaining the entire symptomatology (primary outcome) was 19% (N = 131 of 672) in the SC and 42% (N = 286 of 686) in the IC cohort (OR adjusted for centre effects 3.45 [95% CrI: 1.99–5.65]). The difference was mainly due to a higher prevalence of mental disorders and non-rare somatic diseases in the IC cohort. The median time to explaining diagnoses was one month shorter with IC (95% CrI: 1–2), and significantly more patients could be referred to local regular care in the IC (27.5%; N = 181 of 659) compared to the SC (12.3%; N = 81 of 658) cohort (OR adjusted for centre effects 2.70 [95% CrI: 2.02–3.60]). At 12-month follow-up, patient satisfaction with care was significantly higher in the IC compared to the SC cohort, while quality of life was not different between cohorts. INTERPRETATION: Our findings suggested that including a mental health specialist in the entire evaluation process of CRDs for undiagnosed adolescents and adults should become an integral part of the assessment of individuals with a suspected rare disease. FUNDING: The study was funded by the 10.13039/501100024399Global Innovation Fund from the Joint Federal Committee in Germany (Innovationsfonds des Gemeinsamen Bundesausschusses), grant number 01NVF17031. Elsevier 2023-10-06 /pmc/articles/PMC10579280/ /pubmed/37855024 http://dx.doi.org/10.1016/j.eclinm.2023.102260 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Hebestreit, Helge
Lapstich, Anne-Marie
Brandstetter, Lilly
Krauth, Christian
Deckert, Jürgen
Haas, Kirsten
Pfister, Lisa
Witt, Stefanie
Schippers, Christopher
Dieris-Hirche, Jan
Maisch, Tim
Tüscher, Oliver
Bârlescu, Lavinia
Berger, Alexandra
Berneburg, Mark
Britz, Vanessa
Deibele, Anna
Graeßner, Holm
Gündel, Harald
Heuft, Gereon
Lücke, Thomas
Mundlos, Christine
Quitmann, Julia
Rutsch, Frank
Schubert, Katharina
Schulz, Jörg Bernhard
Schweiger, Susann
Zeidler, Cornelia
Zeltner, Lena
de Zwaan, Martina
Effect of the addition of a mental health specialist for evaluation of undiagnosed patients in centres for rare diseases (ZSE-DUO): a prospective, controlled trial with a two-phase cohort design
title Effect of the addition of a mental health specialist for evaluation of undiagnosed patients in centres for rare diseases (ZSE-DUO): a prospective, controlled trial with a two-phase cohort design
title_full Effect of the addition of a mental health specialist for evaluation of undiagnosed patients in centres for rare diseases (ZSE-DUO): a prospective, controlled trial with a two-phase cohort design
title_fullStr Effect of the addition of a mental health specialist for evaluation of undiagnosed patients in centres for rare diseases (ZSE-DUO): a prospective, controlled trial with a two-phase cohort design
title_full_unstemmed Effect of the addition of a mental health specialist for evaluation of undiagnosed patients in centres for rare diseases (ZSE-DUO): a prospective, controlled trial with a two-phase cohort design
title_short Effect of the addition of a mental health specialist for evaluation of undiagnosed patients in centres for rare diseases (ZSE-DUO): a prospective, controlled trial with a two-phase cohort design
title_sort effect of the addition of a mental health specialist for evaluation of undiagnosed patients in centres for rare diseases (zse-duo): a prospective, controlled trial with a two-phase cohort design
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579280/
https://www.ncbi.nlm.nih.gov/pubmed/37855024
http://dx.doi.org/10.1016/j.eclinm.2023.102260
work_keys_str_mv AT hebestreithelge effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT lapstichannemarie effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT brandstetterlilly effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT krauthchristian effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT deckertjurgen effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT haaskirsten effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT pfisterlisa effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT wittstefanie effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT schipperschristopher effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT dierishirchejan effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT maischtim effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT tuscheroliver effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT barlesculavinia effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT bergeralexandra effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT berneburgmark effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT britzvanessa effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT deibeleanna effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT graeßnerholm effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT gundelharald effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT heuftgereon effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT luckethomas effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT mundloschristine effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT quitmannjulia effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT rutschfrank effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT schubertkatharina effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT schulzjorgbernhard effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT schweigersusann effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT zeidlercornelia effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT zeltnerlena effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT dezwaanmartina effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign
AT effectoftheadditionofamentalhealthspecialistforevaluationofundiagnosedpatientsincentresforrarediseaseszseduoaprospectivecontrolledtrialwithatwophasecohortdesign